This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase - Benchmark Mylan's performance against key rivals in the prescription pharmaceutical sector - Assess how the acquisition of Merck KGaA's generics division will impact Mylan's forecast performance - Consider the impact of Mylan's M&A activity on its geographic presence, reducing its reliance on the US and becoming a global generics player in 2007.
